Pace® Analytical Services Acquires Special Pathogens Laboratory

Pace® Analytical Services, a division of Pace® Science and Technology Company, and preferred provider of in-lab, mobile, and emergency onsite specialty-contaminant and regulatory testing and analysis services, announced Tuesday that it has acquired Special Pathogens Laboratory, the market leader in Legionella testing, detection, remediation, and prevention. Since its inception in 2007, the company has continued the work of preventing outbreaks and advancing research to end Legionnaires’ disease, a lung infection (pneumonia) caused by a bacterium named Legionella pneumophila found in drinking water.

Lighthouse Lab Services, a Portfolio Company of NaviMed Capital, Announces a Majority Growth Recapitalization with Martis Capital

Martis Capital (“Martis”), a middle market private equity firm focused exclusively on the healthcare industry, has made a majority investment in Lighthouse Lab Services (“Lighthouse” or the “Company”), alongside current investors NaviMed Capital (“NaviMed”) and the Company’s management team. Headquartered in Charlotte, North Carolina, Lighthouse is an end-to-end provider of turnkey lab build-out and management services to clinical labs across the United States. The Company provides a comprehensive suite of solutions across outsourced lab management, consulting, recruiting, supply chain management, compliance, equipment sales and more. Lighthouse serves over 1,000 laboratory clients including physician office labs, reference labs, and hospital labs.

Pyxant Labs Acquires Covance by Labcorp’s Salt Lake City Bioanalytical Site

Pyxant Labs Inc., a privately held bioanalytical contract research laboratory, announced Thursday an agreement to acquire Covance by Labcorp’s Salt Lake City bioanalytical site. Pyxant Labs’ Colorado Springs operations and the Salt Lake City site will combine their long-standing reputations, breadth of services, recognized expertise, and exclusive focus on bioanalytical services with the industry-leading cellular imaging and spatial biology capabilities of ImaBiotech.

Exact Sciences Completes Acquisition of Ashion Analytics, LLC, from The Translational Genomics Research Institute, an Affiliate of City of Hope

Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed its previously announced acquisition of Ashion Analytics, LLC. “As a leader in cancer testing, we’re committed to providing earlier answers and life-changing treatment guidance to support patients along every step of their cancer journey,” said Kevin Conroy, chairman and CEO of Exact Sciences. “With Ashion, we’ve added a talented team, a CLIA-certified and CAP-accredited lab, deep sequencing capabilities, and one of the most comprehensive genomic cancer tests available on the market today with GEM ExTra®.”

IQVIA Acquires Remaining Interest in Q2 Solutions from Quest Diagnostics

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced the acquisition of the 40 percent minority share of Q2 Solutions from Quest Diagnostics (NYSE: DGX), the world leader in diagnostic information services, for $760 million, resulting in 100 percent ownership by IQVIA. Q2 Solutions is a leading global clinical laboratory services organization that provides comprehensive testing, project management, supply chain, biorepository and biospecimen and consent tracking solutions for clinical trials.

DiamiR Announces Acquisition of CLIA Lab from Interpace Biosciences

DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that it has entered into a definitive agreement to acquire a CLIA (Clinical Laboratory Improvement Amendments) certified laboratory in New Haven, CT from Interpace Biosciences, Inc. Subject to specific terms and conditions of the agreement being met, it is anticipated that the transaction will close by the end of April, 2021.

Exact Sciences to Acquire Ashion Analytics

Exact Sciences Corp. (Nasdaq: EXAS) announced Tuesday that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The Translational Genomics Research Institute (TGen), an affiliate of City of Hope. Ashion is a CLIA-certified and CAP-accredited sequencing lab based in Phoenix, Arizona with the genomics testing capabilities necessary to address the increasingly complex needs of clinical, academic, and biopharma customers focused on precision cancer treatments.

Thermo Fisher Scientific Acquires Leading Cell Sorting Technology from Propel Labs

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced it has acquired cell sorting technology assets from Propel Labs, a wholly-owned subsidiary of SIDIS Corp. Under the terms of the agreement, the recently introduced Bigfoot Spectral Cell Sorter and approximately 40 employees will become part of Thermo Fisher’s Biosciences business. Propel Labs will continue to operate as a separate entity and serve its existing customers.

HORIBA Acquires MedTest DX and Pointe Scientific to Expand Laboratory Chemistry Offerings

HORIBA, Ltd. (Headquarters in Kyoto, Japan, referred to as HORIBA) and HORIBA Instruments (Headquarters in Irvine, California) announced Tuesday that it has acquired MedTest Holdings, Inc. (Headquarters in Canton, MI, USA, composed of MedTest Dx, Inc., Pointe Scientific, Inc., Clinitox Diagnostix, Inc., and Medical Laboratory Solutions, Inc.). The acquisition will combine the complimentary innovative technology offerings of the HORIBA Medical segment (referred to as HORIBA Medical) with MedTest Dx technology, Clinitox, and Pointe Scientific’s R&D and manufacturing capabilities, with particular expertise in FDA 510K and CLIA clearances, to address the multidisciplinary requirements of IVD1 testing customers.

Charles River Laboratories Acquires Distributed Bio

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it acquired Distributed Bio, Inc. on December 31, 2020. The acquisition marks the culmination of an exclusive partnership between these companies that was initiated in October 2018. Based in South San Francisco, California, Distributed Bio is a next-generation antibody discovery company.